REGENXBIO Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that REGENXBIO Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.04M | Mar 6, 2018 |
| FY2017 | Sep 30, 2017 | $1.34M | Mar 6, 2018 |
| FY2017 | Jun 30, 2017 | $6.56M | Mar 6, 2018 |
| FY2017 | Mar 31, 2017 | $455.0K | Mar 6, 2018 |
| FY2017 | Dec 31, 2016 | $1.70M | Mar 6, 2018 |
| FY2017 | Sep 30, 2016 | $125.0K | Mar 6, 2018 |
| FY2017 | Jun 30, 2016 | $2.38M | Mar 6, 2018 |
| FY2017 | Mar 31, 2016 | $393.0K | Mar 6, 2018 |
| FY2016 | Dec 31, 2015 | $4.44M | Mar 7, 2017 |
| FY2016 | Sep 30, 2015 | $1.14M | Mar 7, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.44M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $83.33M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $90.24M | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | $112.72M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $470.35M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $21.45M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $98.91M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $16.57M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $17.64M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $11.77M | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($193.88M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($227.10M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($263.49M) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | ($280.32M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $127.84M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($46.24M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $8.79M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($33.76M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($40.04M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($26.46M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($161.20M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($233.35M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($268.13M) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | ($262.88M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $159.98M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($119.23M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($149.00M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $88.10M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($75.89M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | ($65.34M) | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $228.30M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $208.52M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $232.27M | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | $242.45M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $181.44M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $47.18M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $43.97M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $38.11M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $37.04M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $33.81M | Mar 1, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($123.96M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($173.13M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($218.41M) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | ($207.49M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $218.88M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($54.06M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($107.71M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $104.65M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($57.99M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | ($48.56M) | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.41M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.44M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $9.96M | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | $30.72M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $84.18M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $26.87M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $11.72M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $13.28M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $7.16M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $8.15M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $453.03M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $465.99M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $573.97M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $833.27M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.11B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $708.16M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $497.91M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $543.81M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $198.68M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $172.73M | Mar 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $350.30M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $206.34M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $262.23M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $317.07M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $349.61M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $330.41M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $47.71M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $34.97M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $15.65M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $11.00M | Mar 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.73M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $259.65M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $311.74M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $516.20M | Mar 13, 2025 |
| FY2024 | Dec 31, 2021 | $764.30M | Mar 13, 2025 |
| FY2023 | Dec 31, 2020 | $377.75M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $450.20M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $508.85M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $183.03M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $161.74M | Feb 26, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.13B) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($932.15M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($705.05M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($441.55M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($161.23M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($289.07M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($177.82M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($83.02M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($187.76M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($114.59M) | Mar 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.47M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $57.53M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $34.52M | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | $96.95M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $345.21M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $338.43M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $69.51M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $75.56M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $46.66M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $24.84M | Feb 27, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | (6) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | (1) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 13, 2025 |
| FY2024 | Dec 31, 2022 | (6) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | (1) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.89M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 49.55M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 44.05M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 43.30M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 42.83M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 37.48M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 36.99M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 36.12M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 31.30M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 26.48M | Mar 6, 2018 |